Loading clinical trials...
Loading clinical trials...
Multicentre observational study of patients with severe tricuspid regurgitation and interventional treatment.
Severe tricuspid regurgitation occurs in around 1.5 % of men and 5.6 % of women and it is associated with significant morbidity and mortality. Current guidelines recommend cardiac surgery, especially in those patients who are undergoing left side valve surgery. Nevertheless many patients are not eligible for surgical tricuspid valve repair due to an high risk of mortality. Therefore interventional devices for treatment of tricuspid regurgitation have been established to offer these patients an alternative treatment option. The aim of this study is to analyse the success and saftey aspects of different interventional repair techniques for severe tricuspid regurgitation. Therefore in this prospectively designed observational study clinical, echocardiographic and laboratory parameters will be collected.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Klinikum der LMU Muenchen
Munich, Germany
Start Date
October 1, 2020
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2030
Last Updated
December 4, 2020
600
ESTIMATED participants
Interventional treatment of tricuspid regurgitation
DEVICE
Lead Sponsor
LMU Klinikum
Collaborators
NCT07433504
NCT05208567
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03142152